Immunodominant antigens of Streptococcus mutans in dental caries–resistant subjects

Gregory, Richard L.; Hobbs, Laura C.; Kindle, Janice C.; VanTo, Tracy; Malmström, Hans

doi:10.3233/hab-1990-1303

Cited by 13 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous studies in immunized animals and naturally-sensitized human subjects have demonstrated the relevance of the humoral immune response against S. mutans P1 (AgI/II, PAc) in protection against bacterial colonization and cariogenicity (reviewed in [3, 11, 18, 19]). Salivary as well as serum antibodies against S. mutans that gain access to the oral cavity via transudation through the gingival crevice have been reported to be protective [6, 20–25], or in some instances non-protective [26–28], depending on the study. This reiterates that subtle and potentially unapparent differences among measured immune responses can be key in determining the ultimate outcome.…”

Section: Introductionmentioning

confidence: 99%

A therapeutic anti-Streptococcus mutans monoclonal antibody used in human passive protection trials influences the adaptive immune response

Robinette

Oli

McArthur

et al. 2011

Vaccine

View full text Add to dashboard Cite

The adhesin known as Antigen I/II, P1 or PAc of the cariogenic dental pathogen Streptococcus mutans is a target of protective immunity and candidate vaccine antigen. Previously we demonstrated that immunization of mice with S. mutans complexed with anti-AgI/II monoclonal antibodies (MAbs) resulted in changes in the specificity, isotype and functionality of elicited anti-AgI/II antibodies in the serum of immunized mice compared to administration of bacteria alone. In the current study, an anti-AgI/II MAb reported in the literature to confer unexplained long term protection against S. mutans re-colonization following passive immunization in human clinical trials (MAb Guy’s 13), and expressed in tobacco plants (MAb Guy’s 13 plantibody), was evaluated for its potential immunomodulatory properties. Immunization of BALB/c mice with immune complexes of Guy’s 13 plantibody bound to S. mutans whole cells resulted in a similar change in specificity, isotype, and functionality of elicited anti-AgI/II antibodies as had been observed for other immunomodulatory MAbs. This new information, coupled with the recently solved crystal structure of the adhesin, now provides a rational explanation and plausible mechanism of action of passively administered Guy’s 13/Guy’s 13 plantibody in human clinical trials, and how long-term prevention of S. mutans carriage well past the application period of the therapeutic antibody could have been achieved.

show abstract

Section: Introductionmentioning

confidence: 99%

A therapeutic anti-Streptococcus mutans monoclonal antibody used in human passive protection trials influences the adaptive immune response

Robinette

Oli

McArthur

et al. 2011

Vaccine

View full text Add to dashboard Cite

show abstract

“…These studies were carried out with informed consent and were approved by the Institutional Review Board of Indiana University‐Purdue University at Indianapolis. Subjects were screened twice for the number of decayed, missing, and filled surfaces (DMFS) as described earlier (14) at baseline and 12 months later. Volunteers who remained free of carious lesions over the 12‐month interval were designated ‘no active caries’ subjects.…”

Section: Methodsmentioning

confidence: 99%

“…Salivary immunoglobulin A (IgA) reacts with S. mutans , and is considered an important factor for host defense against S. mutans for the prevention of dental caries through bacteriostasis (5, 7, 15). We have previously reported that the saliva of caries‐resistant subjects contains higher levels of IgA antibody against many S. mutans epitopes than the saliva of caries‐susceptible patients (14, 15, 25). In the present study, we attempted to identify the S. mutans cellular proteins recognized by IgA in human saliva from various caries‐defined populations and to compare expression of biofilm proteins with planktonic proteins using two‐dimensional gel electrophoresis.…”

mentioning

confidence: 99%

Analysis of Streptococcus mutans biofilm proteins recognized by salivary immunoglobulin A

Sanui

Gregory

2009

Oral Microbiology and Immunology

View full text Add to dashboard Cite

The bacterial molecules recognized by caries-free saliva are significant factors for S. mutans caries formation, and their inhibition could be a therapeutic target. In addition, saliva of caries-free subjects includes significant IgA antibody against antigen I/II of S. mutans, indicating a protective mechanism. However, microorganisms may protect themselves from host immune attack by forming biofilms and decreasing expression of antigen I/II.

show abstract

“…On the other hand, they may eradicate microbes from the mucosal surface, as demonstrated for Respiratory Syncytial Virus (RSV) and Haemophilus influenzae in the respiratory tract [33,34], or Vibrio cholera, Helicobacter felis and Salmonella typhimurium in the gut [35][36][37]. Although persistent colonization or eradication may be determined by the quantity of the local antibodies [38,39], there is also evidence that their specificity to the different microbial epitopes [40], as well as their avidity [41], is important. In our study, women colonized with GBS had low proportions of IgG antibodies to CPS III and protein R 4 compared to whole-cell GBS, in contrast to non-colonized women.…”

Section: Discussionmentioning

confidence: 99%

Cervical Secretions in Pregnant Women Colonized Rectally with Group B Streptococci have High Levels of Antibodies to Serotype III Polysaccharide Capsular Antigen and Protein R

et al. 1998

View full text Add to dashboard Cite

Immunol 1998;47:179-188 Group B streptococci (GBS) colonizing the female genital tract will often infect newborn infants during delivery. In 200 pregnant women studied, 14% were colonized with GBS in the cervix, 12% in the rectum, and 9% in both cervix and rectum. We have previously reported that antibody levels to GBS serotypes Ia, II, and III in sera and cervical secretions were increased in women colonized in the rectum and/or cervix, when analyzed by a whole-cell ELISA. Here, we report the levels of antibodies to GBS serotype III capsular polysaccharide antigen (CPS III) and to protein antigen R 4 , which are present in most GBS III strains. Compared to culture-negative women, the group of women colonized rectally had markedly elevated levels of immunoglobulin (Ig)A and IgG antibodies in cervical secretions to both CPS III and protein R 4 (P < 0.01 and P < 0.001, respectively). In sera, the corresponding differences between culture-negative and culture-positive women were less pronounced, or not present. In contrast to antibody levels to whole-cell GBS, antibody levels to CPS III and protein R 4 in cervical secretions were not significantly increased in women colonized only in the cervix, except that IgA antibodies to protein R 4 were slightly elevated (P < 0.05). These findings suggest that capsular type-specific polysaccharides and protein R 4 in a mucosal vaccine might induce protective antibodies against GBS colonization of the uterine cervix.

show abstract

Immunodominant antigens of Streptococcus mutans in dental caries–resistant subjects

Cited by 13 publications

References 16 publications

A therapeutic anti-Streptococcus mutans monoclonal antibody used in human passive protection trials influences the adaptive immune response

A therapeutic anti-Streptococcus mutans monoclonal antibody used in human passive protection trials influences the adaptive immune response

Analysis of Streptococcus mutans biofilm proteins recognized by salivary immunoglobulin A

Cervical Secretions in Pregnant Women Colonized Rectally with Group B Streptococci have High Levels of Antibodies to Serotype III Polysaccharide Capsular Antigen and Protein R

Contact Info

Product

Resources

About